SynthesisFrontiers in pharmacology2026
Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Refractory chronic cough and unexplained chronic cough are increasingly understood as clinical expressions of cough hypersensitivity. P2X3 receptor antagonists have been developed to reduce ATP-mediated airway sensory nerve activation, but their benefit must be balanced against taste-related adverse events. Methods: Randomized placebo-controlled trials evaluating oral P2X3 receptor antagonists in adults with refractory or unexplained chronic cough were included. Objective cough frequency and taste-related adverse events were selected as primary efficacy and safety/tolerability outcomes. Secondary outcomes included Leicester Cough Questionnaire (LCQ) total score, cough severity visual analogue scale (VAS), overall adverse events, and discontinuation due to adverse events. Effects were pooled using random-effects inverse-variance models. Sensitivity analyses, publication-bias assessment, and GRADE certainty ratings were performed. Results: Eleven trial reports involving 3568 participants were included, yielding 13 independent comparisons for objective cough frequency. P2×3 receptor antagonists reduced objective cough frequency compared with placebo (ratio 0.71, 95% CI 0.63-0.79), corresponding to a 29.3% relative reduction. They also improved LCQ total score (MD 1.44, 95% CI 0.78-2.09) and cough severity VAS (MD -12.73 mm, 95% CI -17.10 to -8.36). Taste-related adverse events were increased (RR 7.36, 95% CI 4.84-11.21), as were overall adverse events (RR 1.21, 95% CI 1.07-1.38) and discontinuation due to adverse events (RR 3.62, 95% CI 2.65-4.93). Leave-one-out analyses did not alter the direction of any pooled estimate. Egger and Begg tests suggested small-study effects for objective cough frequency, but not for safety outcomes with sufficient comparisons. The certainty of evidence was rated as moderate for all prespecified outcomes. Conclusion: P2×3 receptor antagonists were associated with reductions in objective cough frequency and improvements in patient-reported outcomes in refractory or unexplained chronic cough. These benefits should be balanced against increased safety and tolerability concerns, especially taste disturbance, although receptor selectivity appears to attenuate this risk. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261422476.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.